Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Catalyst Pharmaceuticals Inc
CPRX
Healthcare
Biotechnology
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for...
children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CPRX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(231)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 20, 2024 4:00pm
Catalyst Pharmaceuticals to Participate in Upcoming Investor
Just In: $CPRX Catalyst Pharmaceuticals to Participate in Upcoming Investor ConferencesCORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or
...more
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Apr 13, 2023 3:06am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Sep 14, 2022 8:39am
CATALYST PHARMACEUTICALS: NEXT BIG THING ON S&P SMALLCAP 600
$CPRX Excited to share an article about Catalyst Pharmaceuticals, Inc (NASDAQ: CPRX), a commercial-stage biopharmaceutical company that is expected to replace Mantech International Corp (NASDAQ
...more
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Jul 15, 2022 8:29pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Jun 03, 2022 4:13am
FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance
FSD Pharma ready to proceed with Phase 2 clinical trial of FSD
...more
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Jun 01, 2022 11:48pm
FSD Pharma Files Investigational New Drug Application “IND”
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on May 10, 2022 11:48pm
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on May 03, 2022 2:22am
Lucid-MS for Multiple Sclerosis Treatment
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Apr 25, 2022 3:34am
"Julia Levy Award" Recipient David Allan and Dr. John McGraw
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Apr 19, 2022 12:59am
FSD Pharma Inc: Lucid MS Video
FSD Pharma is delighted to announce pre-clinical findings
...more
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Apr 09, 2022 1:06am
FSD: Cancellation of Certain Shares Issued to Former CEO
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A)
...more
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Apr 07, 2022 1:48am
FSD Pharma Issues Corporate Updates
FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to
...more
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Apr 06, 2022 12:56am
iMining: First Hospital Foundation in Decentraland Metaverse
iMining Enters into Agreement for the First-Ever Hospital Foundation to Be Launched in the Decentraland Metaverse Vancouver, British Columbia--(Newsfile Corp.) - iMining Technologies Inc
...more
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Feb 19, 2022 1:01am
FSD Pharma; Recapping 2021 and What to Look Forward in 2022
(0)
•••
Eevhie
X
View Profile
View Bullboard History
Post by
Eevhie
on Feb 05, 2022 2:27am
FSD Pharma Inc: Lucid MS Video
FSD Pharma is pleased to share pre-clinical data demonstrating the effectiveness of its lead drug candidate, Lucid-MS, in treating Multiple Sclerosis. The unique potential therapeutic value of Lucid
...more
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >